UY25926A1 - Formulaciones farmaceuticas de ester tetrahidro-3-furanilico del acido 3s-(3r*(1r*,2s*))-(3-(((4-aminofenil)sulfonil)(2-metilpropil)-amino)-2-hidroxi-1-fenilmetil)propil carbamico - Google Patents
Formulaciones farmaceuticas de ester tetrahidro-3-furanilico del acido 3s-(3r*(1r*,2s*))-(3-(((4-aminofenil)sulfonil)(2-metilpropil)-amino)-2-hidroxi-1-fenilmetil)propil carbamicoInfo
- Publication number
- UY25926A1 UY25926A1 UY25926A UY25926A UY25926A1 UY 25926 A1 UY25926 A1 UY 25926A1 UY 25926 A UY25926 A UY 25926A UY 25926 A UY25926 A UY 25926A UY 25926 A1 UY25926 A1 UY 25926A1
- Authority
- UY
- Uruguay
- Prior art keywords
- amino
- hydroxy
- methylpropyl
- ester
- carbamic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Formulaciones que contienen inhibidores de la proteasa del VIH, especialmente que incluyen el éster tetrahidro-3-furanilico del ácido 3S-[3R*(1R*,2S*)]-[3-[(4-aminofenil)sulfonil] (2-metilpropil)-amino]-2-hidroxi-1-fenilmetil) propil carbamico; (3-(S)-N-(3-tetrahidrofura-niloxicarbonil)amino-1-(N,N-isobutil-4-aminobencenosulfonil)amino-2-(S)-hidroxi-4-fenilbutano; 4-amino-N-(2(R)-hidroxi-4-fenil-3-(S)-(tetrahidrofuran-3-(S)-iloxicarbonil-amino)butil)-N-isobutilbencenosulfonamida (conocido alternativamente como VX 478 o 141W94), que se muestra como estructura del compuesto de fórmula (I), y un tocoferol y el uso de los mismos en la terapia medica. Los inhibidores de la proteasa del VIH tienen potente actividad contra el virus de la Inmunodeficiencia Humana, agente causante del Síndrome de inmunodeficiencia adquirida (SIDA) y las condiciones relacionadas, tales como el complejo relacionado con el Sida (CRS). El compuesto de fórmula (I) es especialmente efectivo como inhibidor del VIH-1 y del VIH-2.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1389396P | 1996-03-22 | 1996-03-22 | |
| GBGB9606372.2A GB9606372D0 (en) | 1996-03-26 | 1996-03-26 | Pharmaceutical formulations |
| US08/820,848 US6730679B1 (en) | 1996-03-22 | 1997-03-20 | Pharmaceutical formulations |
| PCT/EP1997/001438 WO1997035587A1 (en) | 1996-03-22 | 1997-03-21 | Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY25926A1 true UY25926A1 (es) | 2000-09-29 |
Family
ID=27268205
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY25926A UY25926A1 (es) | 1996-03-22 | 2000-01-17 | Formulaciones farmaceuticas de ester tetrahidro-3-furanilico del acido 3s-(3r*(1r*,2s*))-(3-(((4-aminofenil)sulfonil)(2-metilpropil)-amino)-2-hidroxi-1-fenilmetil)propil carbamico |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0906107B1 (es) |
| CN (1) | CN1225587A (es) |
| AP (1) | AP1150A (es) |
| AT (1) | ATE230602T1 (es) |
| AU (1) | AU724239B2 (es) |
| BR (1) | BR9708238A (es) |
| CA (1) | CA2249336C (es) |
| CY (1) | CY2444B1 (es) |
| CZ (1) | CZ289958B6 (es) |
| DE (1) | DE69718315T2 (es) |
| DK (1) | DK0906107T3 (es) |
| EA (1) | EA001484B1 (es) |
| EE (1) | EE04093B1 (es) |
| ES (1) | ES2190528T3 (es) |
| GE (1) | GEP20012464B (es) |
| HK (1) | HK1016896A1 (es) |
| IS (1) | IS2066B (es) |
| NO (1) | NO317639B1 (es) |
| NZ (1) | NZ331645A (es) |
| RO (1) | RO119923B1 (es) |
| SI (1) | SI0906107T1 (es) |
| SK (1) | SK284244B6 (es) |
| TR (1) | TR199801881T2 (es) |
| UY (1) | UY25926A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114366808B (zh) * | 2021-12-14 | 2023-10-13 | 南京农业大学 | 一种多糖和病毒抗原共递送纳米疫苗、其制备方法及应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) * | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| GB9409778D0 (en) * | 1994-05-16 | 1994-07-06 | Dumex Ltd As | Compositions |
| WO1996036316A1 (en) * | 1995-05-19 | 1996-11-21 | Abbott Laboratories | Self-emulsifying formulations of lipophilic drugs |
-
1997
- 1997-03-21 AT AT97914287T patent/ATE230602T1/de active
- 1997-03-21 EP EP97914287A patent/EP0906107B1/en not_active Expired - Lifetime
- 1997-03-21 RO RO98-01407A patent/RO119923B1/ro unknown
- 1997-03-21 GE GEAP19974496A patent/GEP20012464B/en unknown
- 1997-03-21 AP APAP/P/1998/001343A patent/AP1150A/en active
- 1997-03-21 DK DK97914287T patent/DK0906107T3/da active
- 1997-03-21 AU AU21591/97A patent/AU724239B2/en not_active Expired
- 1997-03-21 TR TR1998/01881T patent/TR199801881T2/xx unknown
- 1997-03-21 BR BR9708238A patent/BR9708238A/pt not_active IP Right Cessation
- 1997-03-21 NZ NZ331645A patent/NZ331645A/en not_active IP Right Cessation
- 1997-03-21 DE DE69718315T patent/DE69718315T2/de not_active Expired - Lifetime
- 1997-03-21 EE EE9800323A patent/EE04093B1/xx unknown
- 1997-03-21 CA CA002249336A patent/CA2249336C/en not_active Expired - Lifetime
- 1997-03-21 CN CN97193229A patent/CN1225587A/zh active Pending
- 1997-03-21 EA EA199800755A patent/EA001484B1/ru not_active IP Right Cessation
- 1997-03-21 SI SI9730498T patent/SI0906107T1/xx unknown
- 1997-03-21 ES ES97914287T patent/ES2190528T3/es not_active Expired - Lifetime
- 1997-03-21 CZ CZ19983035A patent/CZ289958B6/cs not_active IP Right Cessation
- 1997-03-21 SK SK1269-98A patent/SK284244B6/sk not_active IP Right Cessation
-
1998
- 1998-08-28 IS IS4840A patent/IS2066B/xx unknown
- 1998-09-21 NO NO19984386A patent/NO317639B1/no not_active IP Right Cessation
-
1999
- 1999-05-12 HK HK99102135A patent/HK1016896A1/xx not_active IP Right Cessation
-
2000
- 2000-01-17 UY UY25926A patent/UY25926A1/es not_active Application Discontinuation
-
2004
- 2004-06-23 CY CY0400050A patent/CY2444B1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA199800755A1 (ru) | 1999-06-24 |
| EE9800323A (et) | 1999-04-15 |
| NZ331645A (en) | 2000-02-28 |
| CA2249336C (en) | 2005-11-22 |
| DE69718315T2 (de) | 2003-10-30 |
| SK126998A3 (en) | 1999-10-08 |
| CZ289958B6 (cs) | 2002-05-15 |
| BR9708238A (pt) | 1999-08-03 |
| NO317639B1 (no) | 2004-11-29 |
| TR199801881T2 (xx) | 1999-01-18 |
| SI0906107T1 (en) | 2003-08-31 |
| AP9801343A0 (en) | 1998-09-30 |
| NO984386L (no) | 1998-11-20 |
| EP0906107B1 (en) | 2003-01-08 |
| CZ303598A3 (cs) | 1999-03-17 |
| AU724239B2 (en) | 2000-09-14 |
| CY2444B1 (en) | 2004-11-12 |
| AP1150A (en) | 2003-03-14 |
| IS4840A (is) | 1998-08-28 |
| ATE230602T1 (de) | 2003-01-15 |
| HK1016896A1 (en) | 1999-11-12 |
| DK0906107T3 (da) | 2003-05-05 |
| EE04093B1 (et) | 2003-08-15 |
| DE69718315D1 (de) | 2003-02-13 |
| IS2066B (is) | 2005-11-15 |
| CN1225587A (zh) | 1999-08-11 |
| SK284244B6 (sk) | 2004-12-01 |
| GEP20012464B (en) | 2001-06-25 |
| NO984386D0 (no) | 1998-09-21 |
| EP0906107A1 (en) | 1999-04-07 |
| CA2249336A1 (en) | 1997-10-02 |
| RO119923B1 (ro) | 2005-06-30 |
| ES2190528T3 (es) | 2003-08-01 |
| EA001484B1 (ru) | 2001-04-23 |
| AU2159197A (en) | 1997-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2072323T3 (es) | Compuestos de piperidina y su preparacion y empleo. | |
| HUP0302980A2 (hu) | Lipofil és ionizálható molekularészeket tartalmazó protein junkinázgátló hatású szulfonamid-származékok és ezeket tartalmazó gyógyszerkészítmények | |
| ES2114471B1 (es) | Nuevos compuestos de paroxetina y procedimiento para su preparacion. | |
| MX9207382A (es) | Nuevos compuestos que tienen actividad terapeutica intermediarios para su preparacion, proceso para obtencion de tales compuestos y formulacion farmaceutica que los contiene. | |
| ATE51522T1 (de) | Formulierung nicht irritierender ophthalmischer waesseriger zusammensetzungen fuer okulartherapeutische mittel. | |
| PT88985A (pt) | Processo para a preparacao de composicoes farmaceuticas nasais e ou oftalmicas contendo azelastina | |
| ES2179910T3 (es) | Modificacion cristalina del cdch, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen. | |
| ES2126766T3 (es) | 7-azaindol-3-ilcarboxiamidas de tropilo como agente antitusivo. | |
| ECSP034883A (es) | Amidas de acidos antranilicos con cadena lateral de heteroarilsulfonilo, procedimiento para su preparacion, su empleo como medicamento o agente de diagnostico, asi como preparados farmaceuticos que las contienen | |
| NO168988C (no) | Anvendelse av en argininiumholdig buffer til formulering av stabile farmasoeytiske preparater inneholdende humanvevplasminogenaktivator | |
| BR0111678A (pt) | Composições medicinais contendo derivados de propenona | |
| MX9400037A (es) | Composicion oftalmica para el tratamiento de glaucoma e hipertension ocular. | |
| DK0572190T3 (da) | Oftalmiske præparater indeholdende vitamin E eller en ester deraf som en aktiv ingrediens | |
| DK0763017T3 (da) | N-(3-amino-2-hydroxybutyl)sulfonamidderivater som HIV-proteaseinhibitorer | |
| ES2067874T3 (es) | Derivados de acetamida. | |
| HUP0004375A2 (hu) | Azelainsavat tartalmazó kompozíció | |
| HUP9801924A2 (hu) | Nátrium/hidrogén-csere inhibitorokat és szív- és keringési zavarok kezelésére alkalmas hatóanyagokat tartalmazó gyógyszerkészítmény | |
| AR006345A1 (es) | Una composicion farmaceutica para administracion oral que comprende un inhibidor de proteasa del vih y un derivado de tocoferol soluble en agua, y un metodo para preparar dicha composicion. | |
| UY25926A1 (es) | Formulaciones farmaceuticas de ester tetrahidro-3-furanilico del acido 3s-(3r*(1r*,2s*))-(3-(((4-aminofenil)sulfonil)(2-metilpropil)-amino)-2-hidroxi-1-fenilmetil)propil carbamico | |
| SE8304616D0 (sv) | Retinaskyddsmedel for behandling av intraokulera blodningar, myopiska korioretinala dystrofier, medfodda retinadystrofier och retinabrennsar samt for forebyggande av skador vid laserkoagulering | |
| AR033779A1 (es) | Compuestos utiles en la enfermedad de reflujo | |
| PE87398A1 (es) | Combinaciones antivirales | |
| ES2138668T3 (es) | Nuevos derivados de peptidos terapeuticamente activos en la cadena de coagulacion sanguinea, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen. | |
| AR004402A1 (es) | Sulfonas ciclicas, procedimiento para prepararlas, preparaciones farmaceuticas que las contienen y empleo de las mismas para combatir enfermedades. | |
| AR007615A1 (es) | Combinaciones antivirales, formulaciones conteniendo las mismas, uso de los mismos en la manufactura de medicamentos y un articulo que los contiene. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RDES | Application refused |
Effective date: 20020218 |